Pharmaceutical company Taiwan Liposome Company Ltd (Nasdaq:TLC)(TWO:4152) revealed on Monday the launch of an exclusive partnership in China to commercialise two liposomal products utilising its proprietary NanoX technology platform in the therapeutic areas of oncology and severe infectious diseases with 3SBio Inc (HKEX:1530).
The partnership allows TLC and 3SBio to obtain regulatory approvals in mainland China; TLC will utilise its commercial-scale manufacturing capabilities to supply the two liposomal products for 3SBio to commercialise in mainland China.
Additionally, the partnership will focus in researching and developing other novel liposomal products in the therapeutic areas of osteoarthritis, pain management, ophthalmology and oncology.
Pursuant to the agreement, TLC is eligible to receive up to USD25m in upfront payments for each product and subsequent regulatory and sales milestone payments as well as is eligible a share of the potential profits from product sales. Additional financial terms were not disclosed.
In conjunction, TLC's NanoX active drug loading technology is designed to alter the systemic exposure of the drug, potentially reducing dosing frequency and enhancing distribution of liposome-encapsulated active agents to the desired site.
Poolbeg PHarma plc receives notice of allowance for POLB 001 patent
RedHill Biopharma secures USPTO Patent for Talicia, extending protection through 2034
Micron Biomedical names new scientific advisor to CEO
Quanterix partners with leading health networks for Alzheimer's diagnosis advancements
Precision BioSciences reports FDA pre-IND feedback for PBGENE-HBV
VBI to sell manufacturing capabilities and enter new license agreement with Brii Biosciences
Ondine Biomedical's Steriwave shows promise in nasal pathogen reduction
BioSenic expands patent coverage for ATO therapeutic platform
PacBio unveils Nanobind PanDNA kit for enhanced DNA extraction solutions
Sequentify receives funding from Israel Innovation Authority
INOVIO plans BLA submission for INO-3107 as RRP treatment
ImmunityBio secures USD320m investment from Oberland Capital
Poolbeg Pharma prioritises promising RSV drug candidates identified through AI-led analysis
GHIT fund invests JPY500m in antimalarial drug clinical trial